openPR Logo
Press release

Dermatophytic Onychomycosis Therapeutics Market: Size, Share, Demand, Trends, and Industry Analysis Statistics Worldwide by 2031 - Kaken Pharmaceutical, Valeant Pharmaceuticals Inc., Galderma S.A.

10-22-2024 01:06 PM CET | Health & Medicine

Press release from: DataM Intelligence 4market Research LLP

Dermatophytic Onychomycosis Therapeutics Market

Dermatophytic Onychomycosis Therapeutics Market

The Dermatophytic Onychomycosis Therapeutics Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.

Get a Free Sample PDF - https://datamintelligence.com/download-sample/dermatophytic-onychomycosis-therapeutics-market

The Dermatophytic Onychomycosis Therapeutics Market is estimated to reach at a high CAGR 6.4% during the forecast period 2024-2031.

Dermatophytic onychomycosis, a common fungal nail infection, requires effective therapeutics to manage symptoms and eradicate the fungus. Treatment options include topical antifungal agents such as ciclopirox and efinaconazole, which are applied directly to the affected nails. Systemic treatments, like terbinafine and itraconazole, are often prescribed for more severe cases due to their ability to penetrate nail tissue and provide a higher cure rate .

Key Players

The companies are primarily focusing on strategies such as new product launches to penetrate the fastest-growing emerging markets across the world. The prominent players in Dermatophytic Onychomycosis Therapeutics market research report are:

Kaken Pharmaceutical, Valeant Pharmaceuticals Inc., Galderma S.A., Trumac Healthcare Ltd, Pfizer, Inc., Moberg Pharma AB, Johnson & Johnson Services, Inc., Bayer AG, Dr. Reddy's Laboratories Ltd., Cipla Ltd., Medimetriks Pharmaceuticals, Inc.

Key Development

On March 2, 2020, Kaken Pharmaceutical Co., Ltd. announced that its licensing partner, Main Life Corp., Ltd., launched Jublia (generic name: efinaconazole) in Hong Kong. Jublia is a topical antifungal formulation specifically designed for the treatment of onychomycosis, a common fungal nail infection. In Japan, the product is marketed under the name Clenafin®.

Regions Covered:

The global Dermatophytic Onychomycosis Therapeutics Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa.

☞ North America - US, Canada, Mexico

☞ Europe- Germany, Russia, UK, France, Italy, Rest of Europe

☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific

☞ South America- Brazil, Argentina, Colombia, Rest of South America

☞ Middle East and Africa- Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Israel

Get this Premium Report: https://www.datamintelligence.com/buy-now-page?report=dermatophytic-onychomycosis-therapeutics-market

Market Segments

By Product Type: Nail Paints, Tablets.

By Treatment Type: Topical Mode, Oral Mode of Treatment.

By Distribution Channel: Retail pharmacies, Online Channels, Hospitals & Clinics.

The Dermatophytic Onychomycosis Therapeutics industry is experiencing rapid growth, driven by advancements in medical technologies, increased demand for innovative therapies, and a rising focus on patient-centered care. As these sectors evolve, the need for comprehensive market analysis becomes crucial to understand trends, regulatory changes, and emerging opportunities.

Key Features

Leverage epidemiology insights to tailor precision diagnostics and address region-specific needs.

Meet critical unmet needs in complex conditions with advanced, precise Dermatophytic Onychomycosis Therapeutics industry solutions for better diagnostics and outcomes.

Stay ahead with real-time pipeline analysis, revealing the latest Dermatophytic Onychomycosis Therapeutics innovations and market trends.

Optimize your offerings with competitive pricing analysis, balancing cost-effectiveness and cutting-edge tech.

Protect your innovation with expert patent analysis, ensuring strategic positioning in the Dermatophytic Onychomycosis Therapeutics market.

Gain an edge with comprehensive competitive intelligence, guiding informed decisions in Dermatophytic Onychomycosis Therapeutics

Maximize market presence with brand share analysis, strengthening your position in the Dermatophytic Onychomycosis Therapeutics landscape.

Accurately predict market demand for Dermatophytic Onychomycosis Therapeutics with precise drug sales forecasting insights.

Get Customization in the report as per your requierments: https://datamintelligence.com/customize/dermatophytic-onychomycosis-therapeutics-market

FAQs

Which region is expected to have the highest market Share during the forecast period?

North America is expected to have the highest market share during the forecast period due to increasing number of prescriptions for onychomycosis, and demand for jublia and kerydin.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dermatophytic Onychomycosis Therapeutics Market: Size, Share, Demand, Trends, and Industry Analysis Statistics Worldwide by 2031 - Kaken Pharmaceutical, Valeant Pharmaceuticals Inc., Galderma S.A. here

News-ID: 3704464 • Views:

More Releases from DataM Intelligence 4market Research LLP

United States Natural Astaxanthin Market to Reach USD 1.5 Billion by 2031, Growing at a CAGR of 7.7% | Rising Demand in Nutraceuticals and Aquaculture
United States Natural Astaxanthin Market to Reach USD 1.5 Billion by 2031, Growi …
Global Natural Astaxanthin Market reached US$ 0.84 billion in 2023 and is expected to reach US$ 1.5 billion by 2031, growing with a CAGR of 7.7% during the forecast period 2024-2031. The Natural Astaxanthin Market focuses on the use of astaxanthin, a powerful antioxidant derived from microalgae, in industries like food and beverages, pharmaceuticals, cosmetics, and nutraceuticals. Known for its health benefits, such as reducing inflammation and supporting skin health, the
Remote Browser Isolation Market reached US$ 0.59 billion in 2024 and is expected to reach US$ 5.35 billion by 2032 | Broadcom, Cisco, Cloudflare, ConnX
Remote Browser Isolation Market reached US$ 0.59 billion in 2024 and is expected …
Remote Browser Isolation Market reached US$ 0.59 billion in 2024 and is expected to reach US$ 5.35 billion by 2032, growing with a CAGR of 31.75% during the forecast period 2025-2032. Remote Browser Isolation (RBI) is a cybersecurity technology that separates a user's web browsing activity from their local network and endpoints by running the browser sessions on remote servers. This approach prevents malware, ransomware, and phishing attacks from reaching the
United States Liquid Chromatography Mass Spectrometry Market to Reach USD 19.10 Billion by 2032, Growing at a CAGR of 13.82% | Expanding Applications in Pharma, Biotech, and Food Safety
United States Liquid Chromatography Mass Spectrometry Market to Reach USD 19.10 …
The Liquid Chromatography Mass Spectrometry Market size reached US$ 6.78 billion in 2024 and is expected to reach US$ 19.10 billion by 2032, growing with a CAGR of 13.82% during the forecast period 2025-2032. LC-MS combines liquid chromatography and mass spectrometry for highly sensitive chemical, proteomic, and pharmaceutical analysis. Growth is driven by drug discovery, clinical diagnostics, and environmental testing. Applications include metabolomics, food safety, and biomarker identification. Research labs, pharmaceutical
United States Algae-Based Food Products Market Outlook 2024-2031: Rising Demand for Natural Proteins and Functional Nutrition | Top Companies are Cargill, Incorporated, AlgoSource E
United States Algae-Based Food Products Market Outlook 2024-2031: Rising Demand …
Global Algae-Based Food Products Market reached US$ 2.1 billion in 2023 and is expected to reach US$ 3.8 billion by 2031, growing with a CAGR of 7.69 % during the forecast period 2024-2031. The Algae-Based Food Products Market includes functional foods, beverages, and supplements made from spirulina, chlorella, and other algae. Growth is driven by health trends, vegan diets, and sustainability awareness. Products provide protein, omega-3s, antioxidants, and vitamins. Food manufacturers,

All 5 Releases


More Releases for Dermatophytic

Call for Automation to Drive the Dermatophytic Onychomycosis Therapeutics Market
Advancements in medicine, diagnosis of varieties of illnesses, and increasing elder population at an unprecedented rate have resulted in high demand for novel drugs and therapies for dermatophytic onychomycosis treatment. In 2021, the dermatophytic onychomycosis therapeutics market was valued at nearly US$ 5.5 Bn, and is set to experience a 6.5% CAGR over the forecast period (2022-2031). Presence and availability of a large clinical pipeline with reference to therapeutic approaches based
Dermatophytic Onychomycosis Therapeutics (DOT) Market 2022 | Detailed Report
The research reports on “Dermatophytic Onychomycosis Therapeutics (DOT) Market” report gives detailed overview of factors that affect global business scope. Dermatophytic Onychomycosis Therapeutics (DOT) Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. An exclusive data offered in this report is collected by research and industry experts team. Download FREE Sample
Dermatophytic Onychomycosis Therapeutics (DOT) Market
Market growth is primarily driven by factors such as increase in the prevalence of fungal toe nail infections in the U.S. and Canada, and rising per capita healthcare expenditure across the globe. Easy application of nail paints is also expected to drive demand for dermatophytic onychomycosis drugs. However, adverse effects associated with anti-fungal drugs and lack of awareness about dermatophytic onychomycosis in Asia Pacific, Middle East and Africa, and Latin
Dermatophytic Onychomycosis Market Expected to Witness a Sustainable Growth
According to a new report published by Allied Market Research, titled, " Dermatophytic Onychomycosis Market by Product (Nail Paint and Tablet), Route of Administration (Topical and Oral Therapy), and End User (Hospitals, Dermatology & Podiatry Clinics, Independent Pharmacies, Mail Order Pharmacies, and Drug Stores) - Global Opportunity Analysis and Industry Forecast, 2020-2027". The global market size of Dermatophytic Onychomycosis market is $XX million in 2019 with XX CAGR, and it is
Dermatophytic Onychomycosis Market Poised to Rake US$ 4,706.3 Mn by 2021
Key players of the global dermatophytic onychomycosis therapeutics market include Galderma S.A., Valeant Pharmaceuticals International Inc., Novartis AG, Pfizer Inc., Janssen Pharmaceuticals, and others. Leading companies in this market collaborate with healthcare solutions and services providers in order to advance operational efficiencies and provide improved patient care. Persistence Market Research (PMR) delivers key insights on the global dermatophytic onychomycosis therapeutics Market in its latest report titled “Global Market Study on Dermatophytic
Dermatophytic Onychomycosis Market : Topical segment to account 70% share
The global dermatophytic onychomycosis therapeutics market is anticipated to expand at a healthy CAGR during the forecast period. By product type, the market is segmented into Nail paint and tablet, which is again sub-divided into prescription (Rx) and over-the-counter (OTC) sub segments. The nail paint segment is expected to contribute a maximum share to the global dermatophytic onychomycosis therapeutics market and expand at the fastest CAGR of 8.3% during the